Senores Pharma.

Why is Senores Pharmaceuticals Ltd falling/rising?

As of 09-Jun, Senores Pharmaceuticals Ltd's stock price is rising to 1,093.75, up 8.71% due to strong financial performance, a trend reversal after previous declines, and increased institutional interest. The stock has outperformed the benchmark Sensex significantly over various time frames, reflecting robust growth and investor confidence.

As of 09-Jun, Senores Pharmaceuticals Ltd's stock price is rising, currently at 1,093.75, reflecting an increase of 87.6 points or 8.71%. This upward movement is supported by several factors. The stock has outperformed the sector by 8.03% today and has shown a trend reversal, gaining after three consecutive days of decline. Additionally, the stock reached an intraday high of Rs 1103, marking a 9.63% increase.<BR><BR>Over the past week, the stock has risen by 5.52%, while the benchmark Sensex has declined by 0.98%. In the last month, Senores Pharmaceuticals has increased by 13.16%, contrasting with a 4.41% drop in the Sensex. Year-to-date, the stock has demonstrated a remarkable growth of 33.11%, compared to a 13.26% decline in the benchmark index. Over the past year, it has achieved an impressive return of 104.82%, while the broader market has faced a decline of 10.34%.<BR><BR>The company's strong financial performance also contributes to the stock's rise. It has reported positive results for the last four consecutive quarters, with a net profit after tax of Rs 63.27 crore, growing at 80.72%, and net sales reaching a record high of Rs 175.19 crore. Furthermore, the company has a low debt-to-equity ratio of 0.10, indicating financial stability. <BR><BR>Institutional investors are increasingly participating, having raised their stake by 0.59% in the previous quarter, which reflects confidence in the company's fundamentals. This combination of strong financial results, positive market performance, and increased institutional interest is driving the stock's rise.

Which are the latest news on Senores Pharma.?

Should I buy, sell or hold Senores Pharmaceuticals Ltd?

Are Senores Pharmaceuticals Ltd latest results good or bad?

Senores Pharmaceuticals Ltd's Q4 FY26 results show strong revenue and net profit growth, with a net profit increase of 77.29% year-on-year and net sales up 53.39%. However, declining operating margins and rising interest costs raise concerns about future profitability sustainability.

Senores Pharmaceuticals Ltd's latest results for Q4 FY26 can be considered quite strong in terms of revenue and net profit growth. The company reported a net profit of ₹31.61 crores, which is a remarkable increase of 77.29% year-on-year. Additionally, net sales grew by 53.39% compared to the same quarter last year, reaching ₹175.19 crores. This marks the seventh consecutive quarter of sequential revenue growth, indicating consistent operational momentum and market share gains.<BR><BR>However, there are some concerns regarding profitability metrics. The operating margin (excluding other income) decreased to 27.11% from 29.48% in the previous quarter, which raises questions about the sustainability of the company's pricing power and cost management. Furthermore, the increase in interest costs to ₹8.46 crores, the highest on record, could impact future profitability.<BR><BR>Overall, while the revenue and profit growth figures are impressive, the margin compression and rising costs suggest that investors should monitor the company's ability to maintain its growth trajectory and profitability in the coming quarters.

When is the next results date for Senores Pharmaceuticals Ltd?

The next results date for Senores Pharmaceuticals Ltd is 20 January 2026.

The next results date for Senores Pharmaceuticals Ltd is scheduled for 20 January 2026.

How has been the historical performance of Senores Pharma.?

Senores Pharma experienced significant growth from March 2024 to March 2025, with net sales rising from 214.52 Cr to 398.25 Cr and profit after tax increasing from 32.71 Cr to 58.34 Cr, despite higher raw material and employee costs. Total assets and liabilities both grew to 1,208.19 Cr, while cash flow from financing activities improved significantly.

Answer:<BR>The historical performance of Senores Pharma shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Senores Pharma's net sales increased substantially from 214.52 Cr in March 2024 to 398.25 Cr in March 2025, reflecting strong operational growth. Total operating income followed the same trend, rising to 398.25 Cr from 214.52 Cr. However, raw material costs surged to 91.64 Cr from 31.96 Cr, and employee costs also rose to 60.37 Cr from 35.46 Cr, contributing to a total expenditure of 308.55 Cr, up from 172.92 Cr. Operating profit (PBDIT) improved significantly to 108.96 Cr from 44.42 Cr, with profit before tax reaching 70.57 Cr compared to 24.95 Cr the previous year. Profit after tax also saw an increase to 58.34 Cr from 32.71 Cr. The company's total assets grew to 1,208.19 Cr from 606.92 Cr, while total liabilities increased to 1,208.19 Cr from 606.92 Cr as well. Cash flow from operating activities remained negative at -45.00 Cr, but cash flow from financing activities turned positive at 573.00 Cr, leading to a net cash inflow of 97.00 Cr, up from 7.00 Cr. Overall, Senores Pharma demonstrated robust growth in revenue and profitability, alongside increased asset and liability levels.

Is Senores Pharma. overvalued or undervalued?

As of September 18, 2025, Senores Pharma is considered very expensive and overvalued with a PE ratio of 56.49 and lower returns compared to peers, despite a year-to-date stock performance of 25.84% against the Sensex's 6.24%.

As of 18 September 2025, the valuation grade for Senores Pharma has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued, with a PE ratio of 56.49, an EV to EBIT of 44.43, and an EV to EBITDA of 36.09. These ratios are considerably higher than its peers, such as Sun Pharma, which has a PE ratio of 34.46 and an EV to EBITDA of 23.34, and Cipla, which boasts a more attractive PE ratio of 23.65 and an EV to EBITDA of 16.67.<BR><BR>In comparison to its industry, Senores Pharma's financial metrics suggest that it is not only overvalued but also lacks competitive returns, as evidenced by its ROE of 7.45% and ROCE of 10.18%. While the stock has outperformed the Sensex year-to-date with a return of 25.84% compared to the Sensex's 6.24%, the overall valuation metrics indicate that investors may be paying a premium that is not justified by the company's financial performance.

How big is Senores Pharma.?

As of 24th July, Senores Pharmaceuticals Ltd has a market capitalization of 2,975.00 Cr, with recent net sales of 435.61 Cr and a net profit of 65.47 Cr. The company's shareholder's funds are 204.27 Cr, and total assets amount to 606.92 Cr.

As of 24th July, Senores Pharmaceuticals Ltd has a market capitalization of 2,975.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Senores Pharmaceuticals reported Net Sales of 435.61 Cr and a Net Profit of 65.47 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 204.27 Cr and Total Assets of 606.92 Cr.

Who are the peers of the Senores Pharma.?

Senores Pharma's peers include Gufic BioScience, Advanced Enzyme, Morepen Labs, Indoco Remedies, IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, SMS Pharma, and Zota Health Care. Management risk varies from excellent at Gufic BioScience and Advanced Enzyme to below average at Senores Pharma, with growth rated as excellent for Senores Pharma and average for most others.

Peers: The peers of Senores Pharma. are Gufic BioScience, Advanced Enzyme, Morepen Labs., Indoco Remedies, IOL Chemicals, Panacea Biotec, Novartis India, Solara Active, SMS Pharma, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Gufic BioScience and Advanced Enzyme, while Average management risk is found at Morepen Labs., Indoco Remedies, IOL Chemicals, Novartis India, SMS Pharma., and the rest. Below Average management risk is noted at Senores Pharma., Panacea Biotec, and Solara Active. Growth is Excellent at Senores Pharma., Good at Morepen Labs. and Novartis India, while Average growth is seen at Indoco Remedies, and the rest. Below Average growth is recorded at Advanced Enzyme, IOL Chemicals, Panacea Biotec, Solara Active, and Zota Health Care. Capital Structure is Excellent at Gufic BioScience, Advanced Enzyme, IOL Chemicals, and Novartis India, while Good capital structure is noted at Senores Pharma., Average at Indoco Remedies and SMS Pharma., and Below Average at Panacea Biotec and Solara Active.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 215.30%, while the lowest is Advanced Enzyme at -12.83%. Senores Pharma.'s 1-year return is not available for comparison. Additionally, peers with negative six-month returns include Gufic BioScience and Advanced Enzyme.

What is the technical trend for Senores Pharma.?

As of March 10, 2025, Senores Pharma's technical trend is neutral with no strong signals, as indicators like MACD and RSI show a sideways movement, despite recent outperformance against the Sensex.

As of 10 March 2025, the technical trend for Senores Pharma has changed to sideways. The current technical stance is neutral, with no strong bullish or bearish signals evident. The MACD, RSI, and other indicators do not provide clear directionality on the weekly or monthly time frames. The Dow Theory indicates no trend on the weekly and monthly levels, and the On-Balance Volume (OBV) also shows no trend. The stock's recent performance has outpaced the Sensex over the past week and month, but the year-to-date return is negative, suggesting mixed sentiment. Overall, the lack of definitive indicators keeps the outlook neutral.

Who are the top shareholders of the Senores Pharma.?

The top shareholders of Senores Pharma include promoter Swapnil Jatin Shah with 7.72%, Aditya Birla Sun Life Insurance Company Limited at 3.71%, mutual funds with 3.23%, foreign institutional investors holding 4.17%, and individual investors collectively owning 31.43%.

The top shareholders of Senores Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Swapnil Jatin Shah, owning 7.72% of the company. Additionally, Aditya Birla Sun Life Insurance Company Limited is the highest public shareholder, holding 3.71%. The company also has mutual funds holding 3.23% across five schemes and foreign institutional investors (FIIs) holding 4.17% through 21 different entities. Individual investors collectively hold 31.43% of the shares.

What does Senores Pharma. do?

Senores Pharmaceuticals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 114 Cr and a net profit of 18 Cr for March 2025. It was incorporated in 2017 and became a public company in 2023.

Overview: <BR>Senores Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Senores Pharmaceuticals Ltd was originally incorporated as "Senores Pharmaceuticals Private Limited" in 2017. The company transitioned to a Public Limited Company and changed its name to "Senores Pharmaceuticals Limited" in 2023. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 114 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 18 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 2,453 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 41.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.09 <BR>Return on Equity: 7.45% <BR>Price to Book: 3.09 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Has Senores Pharma. declared dividend?

No Dividend History Available